Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Mixed Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq futures sink as Amazon, Intel intensify AI spending fears
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
Tweet
Share
E-mailGet Alerts CYCC Hot Sheet
Price: $6.37 --0%
Financial Fact:
Net loss applicable to common shareholders: -3M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Financial Fact:
Net loss applicable to common shareholders: -3M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q3 EPS of ($0.07), $0.01 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $159 thousand versus the consensus estimate of $180 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
- Mammoth Energy Services (TUSK) Reports Q3 EPS of $0.01
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
